🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of the Impact of Electronic Monitoring on Patient Compliance in Hematology

RecruitingNAAges 18 Years - anyAllPrivate Hospital of Confluent, France
NCT06713811 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Management of hemopathies has progressed with the arrival of new drugs such as CAR T-cells (Chimeric Antigen Receptor T-cells), immunotherapy and targeted therapies, while increasing emphasis is being placed on outpatient care. The emergence of oral therapies has simplified the treatment pathway, but they are not without their undesirable effects, which can sometimes lead to treatment suspension or even discontinuation. These undesirable effects may be related either to the haemopathy (pain, general signs, fatigue, malnutrition, infection, etc.), or to the toxicity of the treatments, or to co-morbidities. It is therefore essential to detect and manage these adverse effects in real time. In patients treated with oral therapy, poor compliance (\<80% of doses taken) can have a direct impact on progression-free survival and sometimes on overall survival (Dashputre et al, Williams et al).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Follow-up for haemopathy justifying initiation of oral therapy (one or more authorized molecules) for more than 6 months (1st line of treatment or more), * Intravenous treatment may be associated with it, in accordance with international recommendations (immunotherapy, corticosteroid therapy, other), * Patient affiliated to a social security scheme, * Patient having given written consent prior to any specific study procedure. Exclusion Criteria: * Oral treatment expected to last \< 6 months, * Cerebral tumor involvement, * Other active cancer \< 3 years, excluding skin, prostate and cervical carcinomas treated by surgery alone, * Pregnancy or breast-feeding * Persons deprived of their liberty, under guardianship or curatorship, * Dementia, mental alteration or psychiatric pathology that could compromise the patient's informed consent and/or compliance with the protocol and trial follow-up, * Patient unable to undergo protocol monitoring for psychological, social, family or geographical reasons. * No Internet connection * No telephone line
💊

What it tests

  • Telemonitoring
📍

Where

3 sites
Clinique de l'Europe
Amiens, France
Clinique de la Baie
Morlaix, France
Hôpital Privé du Confluent
Nantes, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy